galectin-slider-v1-670x220

News

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

September 25, 2017 | Press Release

Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02

September 12, 2017 | Press Release

Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 5, 2017 | Press Release

Videos

Why did you choose to become the CEO of Galectin Therapeutics?

Are you conducting clinical trials with GR-MD-02? What results have you seen so far?

Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?

Why are the results of the GR-MD-02 psoriasis study so promising?

Why is the NASH-CX trial so important?

Galectin Therapeutics, Inc.

NASDAQ: GALT

Financial Tear Sheet
Filings & Reports

Stock price updates every 30 minutes.

Corporate Snapshot

Subscribe